Evidence of tachyphylaxis associated with salmeterol treatment of chronic obstructive pulmonary disease patients
2006; Wiley; Volume: 60; Issue: 4 Linguagem: Inglês
10.1111/j.1368-5031.2006.00849.x
ISSN1742-1241
AutoresV. Tsagaraki, Anastasia Amfilochiou, Sophia L. Markantonis,
Tópico(s)Respiratory and Cough-Related Research
ResumoInternational Journal of Clinical PracticeVolume 60, Issue 4 p. 415-421 Evidence of tachyphylaxis associated with salmeterol treatment of chronic obstructive pulmonary disease patients V. Tsagaraki, V. Tsagaraki School of Pharmacy,1Laboratory of Biopharmaceutics and Pharmacokinetics, University of Athens, Sismanoglio General Hospital of Athens,23rd Department of Chest Medicine, Laboratory of Lung Function Tests, Athens, GreeceSearch for more papers by this author 1 A. Amfilochiou, A. Amfilochiou School of Pharmacy,1Laboratory of Biopharmaceutics and Pharmacokinetics, University of Athens, Sismanoglio General Hospital of Athens,23rd Department of Chest Medicine, Laboratory of Lung Function Tests, Athens, GreeceSearch for more papers by this author 2 S. L. Markantonis, Corresponding Author S. L. Markantonis School of Pharmacy,1Laboratory of Biopharmaceutics and Pharmacokinetics, University of Athens, Sismanoglio General Hospital of Athens,23rd Department of Chest Medicine, Laboratory of Lung Function Tests, Athens, Greece *Assistant Professor Sophia L. Markantonis, Panepistimiopolis, School of Pharmacy, Laboratory of Biopharmaceutics and Pharmacokinetics, Athens 157 71, Greece Tel.: + 30 210 7274676 Fax: + 30 210 7274027 Email: [email protected]Search for more papers by this author 1 V. Tsagaraki, V. Tsagaraki School of Pharmacy,1Laboratory of Biopharmaceutics and Pharmacokinetics, University of Athens, Sismanoglio General Hospital of Athens,23rd Department of Chest Medicine, Laboratory of Lung Function Tests, Athens, GreeceSearch for more papers by this author 1 A. Amfilochiou, A. Amfilochiou School of Pharmacy,1Laboratory of Biopharmaceutics and Pharmacokinetics, University of Athens, Sismanoglio General Hospital of Athens,23rd Department of Chest Medicine, Laboratory of Lung Function Tests, Athens, GreeceSearch for more papers by this author 2 S. L. Markantonis, Corresponding Author S. L. Markantonis School of Pharmacy,1Laboratory of Biopharmaceutics and Pharmacokinetics, University of Athens, Sismanoglio General Hospital of Athens,23rd Department of Chest Medicine, Laboratory of Lung Function Tests, Athens, Greece *Assistant Professor Sophia L. Markantonis, Panepistimiopolis, School of Pharmacy, Laboratory of Biopharmaceutics and Pharmacokinetics, Athens 157 71, Greece Tel.: + 30 210 7274676 Fax: + 30 210 7274027 Email: [email protected]Search for more papers by this author 1 First published: 20 March 2006 https://doi.org/10.1111/j.1368-5031.2006.00849.xCitations: 16Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onEmailFacebookTwitterLinkedInRedditWechat Summary Bronchodilator therapy is lifelong mandatory for chronic obstructive pulmonary disease patients. There is evidence of loss of bronchodilator effectiveness over time with β2-agonists but not with anticholinergics. The aim of this study was to examine the development of tachyphylaxis to the long-acting β2-agonist salmeterol using as a control therapeutic regimen the combination of ipratropium bromide and salbutamol sulphate. Fifty-six subjects participated in a 20-week, crossover randomised clinical trial. The parameters forced expiratory volume at 1 s (FEV1), peak expiratory flow rate (PEFR) and FEV1/forced vital capacity were measured via spirometry and the parameters ▵FEV1%pre, ▵PEFR%pre and ▵AUC0−2 h were calculated. FEV1 increased significantly after two weeks of treatment with the combination treatment but not with the salmeterol. The observed diminished increase could be attributed to the development of tolerance to the long acting β2-agonist. Salmeterol seems to be an effective bronchodilator, however, its duration of action over time and its peak effect might be subject to tachyphylaxis. References 1 Inman WHW, Adelstein AM. Rise and fall of asthma mortality in England and Wales in relation to use of pressurised aerosols. Lancet 1969; 2: 279–85. 2 Conolly ME, Davies DS, Dollery CT et al. Resistance to beta-adrenoceptors stimulants. Br J Clin Pharmacol 1971; 43: 389–402. 3 Boulet LP. Long versus short term β2-agonists. Implications for asthma management. Drugs 1994; 47: 207–22. 4 Malo JL, Ghezzo H, Trudeau C et al. Salmeterol, a new inhaled beta 2-adrenergic agonist, has a longer blocking effect than albuterol on hyperventilation-induced bronchoconstriction. J Allergy Clin Immunol 1992; 89: 567–74. 5 Ullman A, Hedner J, Svedmyr N. Inhaled salmeterol and salbutamol in asthmatic patients. An evaluation of asthma symptoms and possible development of tachyphylaxis. Am Rev Respir Dis 1990; 142: 571–5. 6 Boulet LP, Cartier A, Milot J et al. Tolerance to the protective effects of salmeterol on methacholine-induced bronchoconstriction: influence of inhaled corticosteroids. Eur Respir J 1998; 11: 1091–7. 7 Nelson JA, Strauss L, Skowronski M et al. Effect of long-term salmeterol treatment on exercise-induced asthma. N Engl J Med 1998; 339: 141–6. 8 Harvey JE, Tattersfield AE. Airway response to salbutamol inhalations in normal, atopic and asthmatic subjects. Thorax 1982; 37: 280–7. 9 Campbell S. For COPD a combination of ipratropium bromide and albuterol sulfate is more effective than albuterol base. Arch Intern Med 1999; 159: 156–60. 10 Friedman M, Serby CW, Menjoge SS et al. Pharmacoeconomic evaluation of a combination of ipratropium plus albuterol compared with ipratropium alone and albuterol alone in COPD. Chest 1999; 115: 635–41. 11 American Thoracic Society. Standardization of Spirometry – 1994 Update. Am J Respir Crit Care Med 1995; 152: 1107–36. 12 Tashkin DP, Conolly ME, Deutch RI et al. Subsensitization of beta-adrenoceptors in airways and lymphocytes of healthy and asthmatic subjects. Am Rev Respir Dis 1982; 125: 185–93. 13 Holgate ST, Baldwin CJ, Tattersfield AE. Beta adrenergic agonists resistance in normal human airways. Lancet 1975; 2: 375–7. 14 Thiadens HA, De Bock GH, Van Houwelingen JC et al. Can peak expiratory flow measurements reliably identify the presence of airway obstruction and bronchodilator response as assessed by FEV(1) in primary care patients presenting with a persistent cough? Thorax 1999; 54: 1055–60. 15 Grove A, Lipworth BJ, Reid P et al. Effects of regular salmeterol on lung function and exercise capacity in patients with chronic obstructive airways disease. Thorax 1996; 51: 689–93. 16 Rennard SI, Serby CW, Ghafouri M et al. Extended therapy with ipratropium is associated with improved lung function in patients with COPD. A retrospective analysis of data from seven clinical trials. Chest 1996; 110: 62–70. 17 Georgopoulos D, Wong D, Anthonisen NR. Tolerance to beta 2-agonists in patients with chronic obstructive pulmonary disease. Chest 1990; 97: 280–4. 18 Mahler DA, Donohue JF, Barbee RA et al. Efficacy of salmeterol xinafoate in the treatment of COPD. Chest 1999; 115: 957–65. 19 Donohue JF, Van Noord IA, Bateman E et al. A 6 month, placebo-controlled study comparing lung function and health status changes in COPD patients treated with tiotropium or salmeterol. Chest 2002; 122: 47–55. 20 Donohue JF, Menjoge S, Kesten S. Tolerance to bronchodilating effects of salmeterol in COPD. Respir Med 2003; 97: 1014–20. 21 Cheung D, Timmers MC, Zwinderman AH et al. Long-term effects of a long-acting beta 2-adrenoceptor agonist, salmeterol, on airway hyperresponsiveness in patients with mild asthma. N Engl J Med 1992; 327: 1198–203. 22 Meyer JM, Wenzel CL, Kradjan WA. Salmeterol: a novel, long-acting beta 2-agonist. Ann Pharmacother 1993; 27: 1478–87. 23 Ramage L, Lipworth BJ, Ingram CG et al. Reduced protection against exercise induced bronchoconstriction after chronic dosing with salmeterol. Respir Med 1994; 88: 363–8. 24 Bhagat R, Kalra S, Swystun VA et al. Rapid onset of tolerance to the bronchoprotective effect of salmeterol. Chest 1995; 108: 1235–9. 25 Karla S, Swystun VA, Bhagat R et al. Inhaled corticosteroids do not prevent the development of tolerance to the bronchoprotective effect of salmeterol. Chest 1996; 109: 953–6. 26 Drotar DE, Davis EE, Cockcroft DW. Tolerance to the bronchoprotective effect of salmeterol 12 hours after starting twice daily treatment. Ann Allergy Asthma Immunol 1998; 80: 31–4. 27 Sears MR. Asthma treatment: inhaled beta-agonists. Can Respir J 1998; 5 (Suppl. A): 54–9A. 28 Dottorini ML, Tantucci C, Peccini F et al. Diurnal change of bronchial caliber and airway responsiveness in asthmatics during long-term treatment with long-acting beta 2-agonist salmeterol. Int J Clin Pharmacol Ther 1996; 34: 438–43. Citing Literature Volume60, Issue4April 2006Pages 415-421 ReferencesRelatedInformation
Referência(s)